Supriya Lifescience Ltd

₹984.8▼ -0.01%28 Sept

📊 Stock Analysis

Market Data

Market Cap₹7,925.95 Cr.

52W High₹1,085.5

Current Price₹984.8

52W Low₹545.65

Down from 52W High9.3 %

Face Value₹2

Performance

ROCE22.43 %

ROE16.56 %

EPS (TTM)₹2.99

EPS Prev Qtr₹9.22

EPS Last Year₹6.27

EBITDA Qtr₹38.52 Cr.

Book Value₹149

Financial Health

Debt/Equity0

Debt/Profit0.03

Total Assets₹1,357.11 Cr.

Dividend Yield0.1 %

Promoter Holding68.3 %

Earning Power19.08 %

Valuation

Stock P/E39.95

Industry P/E33.81

Price to Book6.62

Price to Sales9.08

Graham Number₹287.24

Key Metrics

__derived

Face Value

₹2

About Supriya Lifescience Ltd

Healthcare · Pharmaceuticals

Supriya Lifescience Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹2. Market cap ₹7,925.95 Cr.

Price Chart

Peer Comparison

Name	CMP	P/E	Market Cap	Div Yield	NP Qtr	Qtr Profit Var%	Sales Qtr	Qtr Sales Var%	ROCE%	Debt/Eq
Sun Pharmaceutical Industries Ltd	-	36.51	₹4,41,477.63 Cr	0.87%	₹12,172.7 Cr	-	₹59,910.52 Cr	-	18.72%	0.05
Divis Laboratories Ltd	-	86.48	₹2,53,031.38 Cr	0.31%	₹2,925 Cr	-	₹11,230 Cr	-	23.04%	0
Torrent Pharmaceuticals Ltd	-	77.67	₹1,85,216.32 Cr	0.78%	₹2,156 Cr	-	₹15,723 Cr	-	15.1%	1.76
Zydus Lifesciences Ltd	-	27.01	₹1,20,897.46 Cr	0.08%	₹4,492.2 Cr	-	₹28,591.7 Cr	-	16.76%	0.43
Cipla Ltd	-	33.28	₹1,12,201.64 Cr	0.94%	₹3,364.84 Cr	-	₹28,324.4 Cr	-	13.24%	0.01
Laurus Labs Ltd	-	99.31	₹1,08,698.22 Cr	0.06%	₹1,090.76 Cr	-	₹7,269.64 Cr	-	20.79%	0.45
Dr Reddys Laboratories Ltd	-	31.6	₹1,02,039.12 Cr	0.65%	₹3,183.3 Cr	-	₹33,227.9 Cr	-	10.05%	0.17
Mankind Pharma Ltd	-	49.29	₹1,00,752.43 Cr	0.04%	₹2,067.57 Cr	-	₹14,737.88 Cr	-	13.95%	0.38
Aurobindo Pharma Ltd	-	26.56	₹97,814.24 Cr	0.24%	₹3,710.8 Cr	-	₹34,935.29 Cr	-	12.75%	0.2
Lupin Ltd	-	16.64	₹94,274.49 Cr	0.87%	₹5,550.99 Cr	-	₹29,966.58 Cr	-	27.95%	0.26
Glenmark Pharmaceuticals Ltd	-	36.67	₹65,922.11 Cr	0.11%	₹1,797.81 Cr	-	₹17,736.56 Cr	-	24.78%	0.25
Alkem Laboratories Ltd	-	28.65	₹61,804.34 Cr	1.03%	₹2,206.3 Cr	-	₹15,081.28 Cr	-	19.75%	0.12
Biocon Ltd	-	110.29	₹61,113.53 Cr	0.13%	₹416.4 Cr	-	₹17,321.1 Cr	-	2.87%	0.43
Abbott India Ltd	-	35.22	₹56,860.69 Cr	1.78%	₹1,614.68 Cr	-	₹7,004.38 Cr	-	45.73%	0
Glaxosmithkline Pharmaceuticals Ltd	-	46.73	₹49,091.33 Cr	1.97%	₹1,068.15 Cr	-	₹3,954.94 Cr	-	64.07%	0
Ipca Laboratories Ltd	-	36.13	₹48,712.48 Cr	0.31%	₹1,379.76 Cr	-	₹10,125.58 Cr	-	21.48%	0.09
Anthem Biosciences Ltd	-	83.03	₹47,949.68 Cr	0.23%	₹575.95 Cr	-	₹2,002.34 Cr	-	25.5%	0.02
Gland Pharma Ltd	-	42.26	₹47,764.08 Cr	0.69%	₹1,128.8 Cr	-	₹6,725.3 Cr	-	15.21%	0.02
Ajanta Pharma Ltd	-	38.87	₹44,109.77 Cr	0.79%	₹1,134.88 Cr	-	₹5,776.17 Cr	-	31.81%	0.05
J B Chemicals & Pharmaceuticals Ltd	-	53.3	₹38,730.77 Cr	0.39%	₹709.46 Cr	-	₹4,147.79 Cr	-	23.03%	0

Quarterly Results

📊 Jun 2026: Revenue grew 30.8% YoY, Profit fell 30.9% YoY

	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	145.08	199.83	206.44	276.53	189.75
↳ QoQ Growth	-	+37.7%	+3.3%	+34.0%	-31.4%
Expenses	99.82	133.83	141.18	187.41	151.23
Operating Profit	45.25	66.01	65.26	89.12	38.52
OPM %	31.19%	33.03%	31.61%	32.23%	20.3%
Other Income	2.67	2.73	2.61	3.48	2.65
Interest	0.51	0.42	0.49	0.47	0.37
Depreciation	6.45	6.64	6.82	8.5	8.94
EBITDA	51.7	72.65	72.08	97.62	47.46
EBITDA Margin %	35.64%	36.36%	34.92%	35.3%	25.01%
Profit Before Tax	47.41	68.32	66.92	92.13	40.79
Tax %	26.62%	26.19%	25.78%	19.43%	41.06%
Net Profit	34.79	50.43	49.68	74.23	24.04
↳ QoQ Growth	-	+45.0%	-1.5%	+49.4%	-67.6%
EPS	4.32	6.27	6.17	9.22	2.99

Profit & Loss

	Mar 2026	TTM
Sales	827.88	872.55
Expenses	562.24	613.65
Operating Profit	265.64	258.91
OPM %	32.09%	29.67%
Other Income	11.49	11.47
Interest	1.89	1.75
Depreciation	28.41	30.9
Profit Before Tax	274.78	268.16
Tax %	23.9%	26.03%
Net Profit	209.13	198.38
EPS	25.98	24.65

Compounded Sales Growth

10Y

TTM

Compounded Profit Growth

10Y

TTM

Stock Price CAGR

10Y

36.23%

Return on Equity

10Y

Last Year

19.9%

Balance Sheet

	Mar 2025	Mar 2026
Equity Capital	16.097	16.1
Reserves	980.663	1181.64
Borrowings	0	5.44
Other Liabilities	115.55	153.93
Total Liabilities	1112.314	1357.11
Fixed Assets	452.866	687.84
CWIP	148.015	35.55
Investments	63.24	98.52
Other Assets	448.19	535.2
Total Assets	1112.314	1357.11

Cash Flows

	Mar 2025
Cash from Operating Activity	164.675
Cash from Investing Activity	-152.244
Cash from Financing Activity	-8.233
Net Cash Flow	4.198

Ratios

	Mar 2026
Debtor Days	-
Inventory Days	-
Days Payable	-
Cash Conversion Cycle	-
Working Capital Days	595.93
ROCE %	19.65%

Shareholding Pattern

	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters %	68.3%	68.3%	68.3%	68.3%
FIIs %	5.46%	5.2%	5.16%	6.19%
DIIs %	5.22%	5.01%	5.7%	5.3%
Public %	16.77%	16.66%	16.22%	15.98%
No. of Shareholders	87,912	85,099	81,161	82,082